Product image of Illuccix (Gozetotide) supplied by GNH India

Illuccix

Active Ingredient:
Gozetotide
Origin:
EU

Illuccix (Gozetotide)

Gozetotide, the active ingredient in Illuccix, is an investigational agent presented as an intravenous formulation for clinical use. It is being evaluated for potential therapeutic applications in various disease areas, though specific approved indications have not been publicly disclosed. The compound is manufactured under strict Good Manufacturing Practice standards and is intended for administration by qualified healthcare professionals in controlled settings.
GNH India supplies Illuccix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide, ensuring quality and regulatory compliance across all markets.

Manufacturer / TM Owner

Telix Innovations

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Illuccix (gozetotide) is currently under clinical investigation, and no specific approved therapeutic indications have been publicly disclosed.

  • Approved indications: not publicly disclosed
  • Investigational use: being studied in clinical trials for potential oncology applications
  • Research focus: evaluation in rare disease cohorts under experimental protocols

How It Works

  • Gozetotide is a peptide‑based molecule that is designed to bind selectively to a specific cellular target involved in disease signaling pathways. By interacting with this target, it modulates downstream cellular processes, potentially altering disease progression. The exact molecular target and pathway have not been fully disclosed in publicly available literature, and the drug remains under clinical evaluation.

Side Effects

The adverse reaction profile of Illuccix (gozetotide) has not been fully disclosed in publicly available sources.

Common Side Effects

  • Infusion‑related reactions such as mild fever, chills, or headache (frequency not publicly disclosed)
  • Nausea or vomiting (frequency not publicly disclosed)
  • Laboratory abnormalities (e.g., transient liver enzyme elevations) (frequency not publicly disclosed)

Serious or Rare Side Effects

  • Severe hypersensitivity or anaphylaxis (frequency not publicly disclosed)
  • Hemodynamic instability or cardiac events (frequency not publicly disclosed)
  • Cytokine release syndrome (rare) (frequency not publicly disclosed)

Precautions & Warnings

When using Illuccix (gozetotide), healthcare professionals should observe standard precautions for investigational intravenous agents.

  • Patient assessment: evaluate baseline health status and organ function before administration
  • Monitoring: observe vital signs and infusion site during and after dosing
  • Contraindications: avoid use in patients with known hypersensitivity to the product
  • Drug interactions: review concomitant medications for potential immunomodulatory effects
  • Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake

Avoid Interactions

Potential drug interactions with Illuccix (gozetotide) have not been fully characterized in publicly available data.

Major Interactions (Avoid)

  • Concurrent use with strong immunosuppressants (risk of additive immunosuppression) (not confirmed)
  • Live vaccines (risk of reduced efficacy) (not confirmed)

Moderate Interactions (Monitor Closely)

  • Anticoagulants (possible increased bleeding risk) (not confirmed)
  • CYP450 substrates (potential metabolic interaction) (not confirmed)
  • Herbal supplements with immunomodulatory properties (monitor patient response) (not confirmed)

Frequently Asked Questions

Illuccix contains the investigational peptide gozetotide and is being evaluated in clinical studies. At present, no specific therapeutic indications have been approved or publicly disclosed, so its use is limited to research protocols and compassionate use programs under medical supervision.

Gozetotide is designed as a peptide that binds selectively to a cellular target involved in disease‑related signaling pathways. By engaging this target, it modulates downstream biological processes that may influence disease progression. The precise molecular target and mechanism remain under investigation and have not been fully disclosed.

Dosing for Illuccix is determined by the prescribing clinician based on the specific clinical trial protocol or individual patient assessment. No standard dose is publicly available, and the regimen should be set by a qualified healthcare professional.

Safety data for gozetotide in pregnant or lactating individuals are limited. Use during pregnancy or breastfeeding is only recommended when the potential therapeutic benefit outweighs any possible risk, and the decision should be made by the treating physician.

To request Illuccix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

Because Illuccix (gozetotide) has not received regulatory approval, direct comparisons with established therapies are limited. It is an investigational agent, and any efficacy or safety advantages over existing treatments remain to be demonstrated in ongoing clinical studies.

Illuccix should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the product. Follow all cold‑chain handling procedures during transport and before administration.

Illuccix is supplied for intravenous infusion. It must be administered by a qualified healthcare professional using aseptic technique, following the specific infusion rate and monitoring guidelines outlined in the clinical protocol or prescribing information.

The most serious potential risks include severe hypersensitivity reactions such as anaphylaxis, cytokine release syndrome, and hemodynamic instability. Patients should be closely monitored during and after infusion for any signs of these reactions, and emergency measures should be readily available.

Illuccix should be avoided in individuals with known hypersensitivity to gozetotide or any of its excipients. Caution is also advised for pregnant or lactating patients, and for those with uncontrolled cardiovascular conditions unless the prescribing physician determines that the potential benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Gozetotide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT